Last reviewed 2026-04-23 · How we verify

Topical tacrolimus or pimecrolimus

Topical tacrolimus and pimecrolimus are calcineurin inhibitors that suppress the immune system by blocking the activation of T-lymphocytes.

Topical tacrolimus and pimecrolimus are calcineurin inhibitors that suppress the immune system by blocking the activation of T-lymphocytes. Used for Moderate to severe atopic dermatitis.

At a glance

Mechanism of action

They work by inhibiting the calcineurin enzyme, which is necessary for the activation of T-lymphocytes. This leads to a decrease in the production of pro-inflammatory cytokines and a reduction in the immune response. As a result, they are effective in treating inflammatory skin conditions such as atopic dermatitis.

Approved indications

• Moderate to severe atopic dermatitis

Common side effects

• Headache
• Pruritus
• Skin burning sensation
• Skin irritation
• Allergic contact dermatitis

Key clinical trials

• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.